Scleroderma, Diffuse clinical trials

The registry lists 310 studies for Scleroderma, Diffuse across more than 10 countries. 76 are recruiting or about to start. 163 of them are mainly about Scleroderma, Diffuse (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Scleroderma, Diffuse studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 149
Recruiting: 55
Terminated: 34
Status unknown: 24
Not yet recruiting: 18
Withdrawn: 13

Phase

Phase 2: 92
Phase 1: 48
Phase 3: 43
Phase 4: 7
Early Phase 1: 5

Where

United States: 153
France: 40
Canada: 34
United Kingdom: 31
Turkey: 26
Spain: 25

Who runs them

University of Michigan (15) · Johns Hopkins University (9) · Lady Davis Institute (9) · Assistance Publique - Hôpitaux de Paris (7) · Istanbul University (6) · Bristol-Myers Squibb (5) · University Hospital, Strasbourg, France (5) · Duke University (5)

What is being tested here

Drugs under test in Scleroderma, Diffuse studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Cyclophosphamide	3	3	7
Fludarabine	2	1	5
Belimumab	2	2	3
Rituximab	1	4	5
Sildenafil	1	2	3
Immunoglobulins, Intravenous	1	1	3
Immunoglobulin G	1	1	3
Hyaluronoglucosaminidase	1	0	2
Tocilizumab	1	1	2
Mesna	1	1	2

Drug classes tested here Alkylating agents 3 open · Antimetabolites 2 open · PDE5 inhibitors 1 open · Endothelin receptor antagonists 10 · Tyrosine kinase inhibitors (TKIs) 5

Coming up

8phase 3 studies under way

27studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Jan 2027Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) · Phase 3 · AstraZeneca
Nov 2026Platform Clinical Study for Conquering Scleroderma · Scleroderma Research Foundation, Inc.
Nov 2026Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Nov 2026Sildenafil for Early Pulmonary Vascular Disease in Scleroderma · Johns Hopkins University
Nov 2026Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis · UMC Utrecht
Nov 2026The Effect of Progressive Muscle Relaxation Exercises on Fatigue, Dyspnea, and Respiratory Function in Patients With Systemic Sclerosis · University of Gaziantep
Dec 2026Elastography Ultrasound in Localized Scleroderma (Morphea) Study · The Hospital for Sick Children
Dec 2026Skeletal Muscle Function in Interstitial Lung Disease · University of British Columbia
Jan 2027A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. · Prolium Bioscience, Inc
Jan 2027Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma · Centre Hospitalier Universitaire Dijon

Who these studies take

Of the 55 Scleroderma, Diffuse studies recruiting now, 28 (51%) set no upper age limit and 20 (36%) stop at 75 or younger. 10 (18%) take children under 18. 3 (5%) are for women only and 0 (0%) for men only; 10 (18%) take healthy volunteers.

Recruiting studies that take each age, of 55
Age	Women	Men
10	10 (18%)	9 (16%)
18	53 (96%)	50 (91%)
30	53 (96%)	50 (91%)
40	54 (98%)	51 (93%)
50	54 (98%)	51 (93%)
65	52 (95%)	49 (89%)
75	40 (73%)	39 (71%)
85	34 (62%)	33 (60%)

Across all 310 studies, recruiting or not: 33% stop at 75 or younger and 13% at 65; 12% take children; 3% are for women only and 0% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Scleroderma, Diffuse studies take

Of 24 phase 2 interventional studies under Scleroderma, Diffuse, half reached primary completion within 48 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	48 mo31–108 · 24 studies	—	—
Interventional, no phase	16 mo4–28 · 53 studies	—	14 mo4–27 · 51 studies
Observational	80 mo44–… · 32 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 11, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 310. Browse all 310 → or search them.